Insight regarding the utilization of antibody-drug conjugate therapy to treat relapsed/refractory advanced bladder cancer.
EP. 1: Advanced Bladder Cancer: Adopting Newer Therapies into Clinical Practice
Bradley McGregor, MD, reacts to treatment advances for advanced bladder cancer and shares perspective on utilizing newer, novel therapies as the field continues to evolve
EP. 2: Encouraging Developments in Therapies for Relapsed/Refractory Advanced Bladder Cancer
Dr Benjamin Miron highlights data specific to treating patients with relapsed metastatic disease.
EP. 3: Treating R/R Advanced Bladder Cancer With Novel Sequencing Strategies
UCSF Health’s Vadim S. Koshkin, MD, highlights approaches for sequencing novel therapies into treatment algorithms for patients with relapsed/refractory advanced bladder cancer.
EP. 4: Study EV-103 in Advanced Bladder Cancer
Ali R. Khaki, MD, describes the impact of the EV-103 study of enfortumab vedotin in advanced bladder cancer.
EP. 5: Optimizing Therapy for Patients with Advanced Bladder Cancer
Ali R. Khaki, MD, comments on how to treat patients with advanced bladder cancer based on data demonstrated by the EV-103 study of enfortumab vedotin.
Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC
Dr Sands on the Evolving Role of ADCs in SCLC Management
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer